Values First Advisors Inc. Makes New $568,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Values First Advisors Inc. bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 6,322 shares of the company’s stock, valued at approximately $568,000.

A number of other institutional investors also recently made changes to their positions in the business. Natixis raised its position in shares of Axsome Therapeutics by 13.6% in the 1st quarter. Natixis now owns 1,235 shares of the company’s stock valued at $99,000 after purchasing an additional 148 shares in the last quarter. Arizona State Retirement System raised its position in shares of Axsome Therapeutics by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 8,630 shares of the company’s stock valued at $695,000 after purchasing an additional 177 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Axsome Therapeutics by 2.9% in the 1st quarter. Principal Financial Group Inc. now owns 9,773 shares of the company’s stock valued at $780,000 after purchasing an additional 276 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Axsome Therapeutics in the 2nd quarter valued at approximately $27,000. Finally, Oak Ridge Investments LLC raised its position in shares of Axsome Therapeutics by 2.7% in the 1st quarter. Oak Ridge Investments LLC now owns 15,930 shares of the company’s stock valued at $1,271,000 after purchasing an additional 413 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Axsome Therapeutics

In related news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares of the company’s stock, valued at $913,282.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the sale, the director now directly owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Mark L. Jacobson sold 47,739 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $84.26, for a total value of $4,022,488.14. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at approximately $487,275.58. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Trading Down 3.8 %

NASDAQ:AXSM opened at $88.83 on Friday. Axsome Therapeutics, Inc. has a 1 year low of $55.02 and a 1 year high of $98.40. The stock has a market cap of $4.22 billion, a price-to-earnings ratio of -13.92 and a beta of 1.26. The business has a fifty day moving average of $90.02 and a 200-day moving average of $81.94. The company has a debt-to-equity ratio of 1.77, a quick ratio of 2.40 and a current ratio of 2.48.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.06. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.85%. The company had revenue of $87.17 million during the quarter, compared to analysts’ expectations of $84.53 million. Equities analysts predict that Axsome Therapeutics, Inc. will post -4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Bank of America raised Axsome Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $95.00 to $106.00 in a research report on Tuesday, August 6th. Wells Fargo & Company initiated coverage on Axsome Therapeutics in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a research report on Monday, September 16th. Royal Bank of Canada upped their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Finally, Needham & Company LLC reissued a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research report on Thursday, September 5th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $124.64.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.